red
cell
alloantigen
exposur
caus
alloantibodyassoci
morbid
murin
model
suggest
inflamm
modul
red
cell
alloimmunis
studi
quantifi
alloimmunis
risk
infecti
episod
human
perform
multicentr
casecontrol
studi
within
sourc
popul
patient
receiv
first
subsequ
red
cell
transfus
followup
period
patient
develop
first
transfusioninduc
red
cell
alloantibodi
n
compar
two
similarli
expos
nonalloimmunis
control
n
alloimmunis
risk
period
use
multivari
logist
regress
analysi
transfus
sever
bacteri
tissueinvas
infect
associ
increas
risk
alloantibodi
develop
adjust
rel
risk
rr
confid
interv
ci
especi
infect
accompani
longstand
fever
rr
ci
dissemin
viral
disord
demonstr
trend
toward
increas
risk
rr
ci
appar
contrast
possibl
protect
associ
gramneg
bacteraemia
rr
ci
simpl
bacteri
infect
gramposit
bacteraemia
fungal
infect
maximum
creactiv
protein
valu
leucocytosi
associ
red
cell
alloimmunis
find
consist
murin
model
confirmatori
research
need
patient
like
develop
alloantibodi
may
identifi
base
infecti
condit
time
transfus
probabl
modul
alloimmunis
identif
factor
might
enabl
alloc
extens
match
blood
princip
highrisk
patient
experiment
induc
inflamm
consist
demonstr
major
determin
red
cell
alloimmunis
mice
hendrickson
et
al
hendrickson
et
al
hendrickson
smith
et
al
line
proinflammatori
condit
relat
sickl
cell
diseas
well
febril
reaction
donor
platelet
shown
enhanc
alloimmunis
human
yazer
et
al
fasano
et
al
apart
one
case
report
hata
et
al
best
knowledg
influenc
infectionassoci
inflamm
red
cell
alloimmunis
human
report
nest
casecontrol
studi
quantifi
rel
alloimmunis
risk
patient
receiv
red
cell
unit
infecti
episod
accord
type
infect
intens
patient
inflammatori
respons
perform
nest
casecontrol
studi
within
sourc
popul
previous
nontransfus
nonalloimmunis
patient
three
univers
hospit
three
refer
hospit
netherland
use
design
compar
patient
develop
red
cell
alloantibodi
follow
transfus
nonalloimmunis
control
basi
suppos
causal
attribut
includ
variou
type
infect
detail
sourc
popul
includ
elig
criteria
casecontrol
studi
design
previous
publish
zalpuri
et
al
ever
et
al
summar
patient
elig
receiv
first
red
cell
transfus
studi
period
one
particip
hospit
provid
transfus
preced
neg
antibodi
screen
follow
antibodi
screen
herebi
permit
evalu
alloantibodi
develop
studi
period
per
hospit
depend
electron
avail
necessari
data
januari
decemb
detail
see
data
red
cell
unit
prepar
buffycoat
deplet
whole
blood
donat
subsequ
filter
leucocyt
deplet
filter
store
salin
adenin
glucos
mannitol
sagm
maximum
day
cbo
patient
defin
case
upon
develop
first
transfusioninduc
red
cell
alloantibodi
direct
one
follow
antigen
c
c
e
e
k
c
w
fy
fy
b
jk
jk
b
lu
lu
b
n
antid
immunis
patient
taken
consider
unabl
discrimin
whether
antid
caus
unmatch
transfus
mainli
regard
fertil
women
due
recent
antid
administr
context
dposit
pregnanc
transfus
patient
form
antibodi
yet
either
lack
exposur
document
assum
antigenposit
red
cell
unit
express
antigen
ie
autoimmunis
patient
deem
inelig
addit
alloimmunis
patient
exclud
firsttim
alloantibodi
posit
screen
occur
within
day
first
mismatch
transfus
like
repres
boost
earlier
primari
immunis
consult
nationwid
alloimmunis
registri
http
wwwsanquinnlproductendienstendiagnostiektrix
addit
exclud
patient
previous
diagnos
alloimmunis
hospit
consid
abovement
criteria
specif
aim
exclud
previous
alloimmunis
patient
includ
pregnancyinduc
immunis
women
final
haemoglobinopathi
patient
infant
month
age
includ
elig
case
match
two
randomli
select
nonalloimmunis
control
patient
base
hospit
lifetim
number
red
cell
transfus
receiv
time
alloimmunis
incidencedens
sampl
strategi
ensur
control
expos
least
amount
transfus
match
case
thu
form
repres
sampl
sourc
popul
rothman
case
assum
last
antigenmismatch
transfus
nth
implic
transfus
preced
first
posit
screen
like
elicit
alloimmunis
last
mismatch
transfus
could
identifi
due
incomplet
type
donor
unit
assum
last
nontest
unit
preced
first
posit
screen
least
day
elicit
alloimmunis
alloimmunis
risk
period
construct
stretch
day
day
implic
nth
transfus
similar
risk
period
around
nth
transfus
determin
match
control
implic
transfus
alloimmunis
risk
period
illustr
fig
case
control
record
variou
clinic
condit
alloimmunis
risk
period
studi
protocol
approv
ethic
review
board
leiden
univers
medic
centr
leiden
local
board
particip
centr
patient
netherland
routin
screen
red
cell
alloantibodi
maximum
h
prior
red
cell
transfus
accord
dutch
transfus
guidelin
cbo
commerci
avail
screen
panel
requir
homozyg
posit
c
c
e
e
k
fy
fy
b
jk
jk
b
presenc
k
antigen
heterozyg
form
minimum
requir
presenc
c
w
lu
wr
kp
mandatori
commerci
avail
screen
cell
cbo
gather
routin
store
data
red
cell
transfus
date
date
result
antibodi
screen
includ
antibodi
specif
patient
date
birth
sex
leucocyt
count
hospit
electron
laboratori
inform
system
addit
examin
medic
chart
case
control
presenc
variou
potenti
clinic
risk
variabl
alloimmunis
risk
period
includ
date
infect
caus
microorgan
date
fever
temperatur
leucocyt
count
creactiv
protein
crp
valu
bacteri
infect
compris
tissueinvas
infect
ie
involv
anatom
site
locat
bacteraemia
ie
involv
posit
blood
cultur
tissueinvas
bacteri
infect
consid
present
confirm
either
posit
blood
tissu
cultur
suspect
clinic
infecti
phenotyp
support
overtli
diseasespecif
radiograph
anomali
eg
clear
lobar
consolid
chest
xray
patient
fever
cough
categor
infect
mild
sever
accord
expect
degre
system
inflamm
mild
tissueinvas
bacteri
infect
includ
routin
tip
cultur
central
cathet
catheterinduc
phlebiti
lower
urinari
tract
infect
bacteri
enter
skin
superfici
wound
infect
upper
respiratori
tract
infect
sever
tissueinvas
bacteri
infect
includ
abscess
intraabdomin
infect
includ
spontan
secondarili
infect
abdomin
fluid
collect
arthriti
bursiti
myositi
fasciiti
infect
haematoma
bacteri
mening
deep
wound
skin
infect
endocard
mediastin
pericard
infect
foreign
materi
lower
respiratori
tract
infect
osteomyel
spondylodisc
upper
urinari
tract
infect
bacteraemia
categor
accord
gramposit
gramneg
caus
microorgan
qualif
viral
infect
posit
polymeras
chain
reaction
pcr
test
demonstr
replic
viral
rna
dna
need
case
pcr
test
perform
clinic
condit
need
clearli
viral
induc
eg
herp
labiali
viraemia
dissemin
viral
zoster
infect
defin
dissemin
viral
infect
contrast
local
viral
infect
restrict
one
anatom
site
locat
associ
variou
infect
develop
red
cell
alloimmunis
evalu
use
logist
regress
analys
crude
rel
risk
rr
calcul
condit
match
variabl
ie
hospit
cumul
number
red
cell
unit
receiv
multivari
analys
also
condit
measur
confound
take
account
confound
meet
prerequisit
associ
exposur
ie
infect
sourc
popul
marker
causal
risk
factor
outcom
ie
alloimmunis
causal
pathway
exposur
outcom
hernan
et
al
middelburg
et
al
consequ
use
follow
strategi
first
identifi
subset
covari
confound
given
determin
base
observ
associ
determin
within
sourc
popul
ie
nonalloimmunis
control
associ
defin
implic
transfus
alloimmunis
risk
period
last
antigenmismatch
transfus
preced
first
serolog
detect
antibodi
defin
implic
nth
transfus
sinc
transfus
like
influenc
alloimmunis
exclud
possibl
boost
event
implic
transfus
requir
preced
first
posit
screen
least
day
ie
lag
period
alloimmunis
risk
period
construct
start
day
finish
day
implic
transfus
control
receiv
least
number
red
cell
unit
match
case
similar
alloimmunis
risk
period
around
nth
match
transfus
construct
differ
covari
presenc
control
expos
control
expos
determin
covari
causal
pathway
determin
outcom
consid
confound
hernan
et
al
second
abl
accur
control
confound
low
preval
estim
probabl
score
determin
use
logist
regress
potenti
confound
predictor
brookhart
et
al
third
minim
bia
due
miss
data
confound
use
multipl
imput
detail
use
imput
model
found
data
tabl
si
final
evalu
associ
variou
type
infect
red
cell
alloimmunis
subsequ
enter
correspond
probabl
score
logist
regress
model
alloimmunis
outcom
condit
match
variabl
next
assess
associ
level
crp
valu
leucocytosi
possibl
marker
inflamm
red
cell
alloimmunis
leucocytosi
categor
maximum
measur
leucocyt
count
l
referenc
normal
count
l
maximum
measur
crp
valu
categor
mgl
referenc
valu
mgl
miss
crp
leucocyt
valu
multipli
imput
use
strategi
describ
likelihood
increas
inflammatori
paramet
record
least
increas
number
measur
thu
durat
hospit
repeat
analys
limit
paramet
measur
within
week
follow
implic
transfus
elev
crp
level
leucocytosi
reflect
variou
clinic
condit
prevent
causal
infer
present
unadjust
rr
anti
antic
w
antil
antil
b
antilu
antim
also
form
natur
eg
directli
respons
microbi
epitop
exposur
reid
et
al
evalu
possibl
associ
presenc
antibodi
variou
type
infect
use
pearson
chisquar
test
pvalu
consid
statist
signific
use
incidencedens
sampl
procedur
select
control
rothman
interpret
present
odd
ratio
rr
confid
interv
ci
patient
presenc
absenc
certain
type
infect
could
determin
patient
left
correspond
analysi
regard
sever
bacteri
infect
perform
sensit
analysi
patient
altern
assign
exposur
nonexposur
infect
patient
suspect
lower
respiratori
infect
without
conclus
avail
cultur
consid
infect
due
bacteri
microorgan
although
viral
rare
fungal
pathogen
may
caus
pneumonia
bacteri
microorgan
common
caus
dutch
hospitalis
patient
streptococcu
pneumonia
haemophilu
influenza
alon
repres
caus
pathogen
wiersinga
et
al
final
contamin
blood
cultur
posit
coagulaseneg
staphylococci
cn
might
dilut
exist
effect
gramposit
bacteraemia
compar
rr
gramposit
bacteraemia
noncn
gramposit
bacteraemia
among
newlytransfus
patient
consid
elig
fig
patient
form
redcel
alloantibodi
thirtyseven
alloimmunis
patient
receiv
unit
cognat
antigen
unknown
assum
last
nontest
unit
preced
first
posit
screen
elicit
alloimmunis
gener
clinic
characterist
case
match
control
alloimmunis
risk
period
present
tabl
among
case
control
patient
diagnos
least
one
infect
alloimmunis
risk
period
suffer
bacteri
infect
viral
infect
fungal
infect
tabl
ii
patient
diagnos
sever
tissueinvas
bacteri
infect
causal
microorgan
identifi
cultur
three
virallyinfect
patient
pcr
test
perform
alloimmunis
risk
period
patient
nevertheless
includ
base
clinic
condit
one
patient
receiv
allogen
stem
cell
transplant
outbreak
varicella
zoster
one
patient
receiv
chemotherapi
burkitt
lymphoma
herp
labiali
one
patient
liver
cirrhosi
due
chronic
hepat
c
infect
identifi
confound
per
alloimmunis
determin
present
tabl
sii
siii
illustr
control
subject
viral
infect
younger
receiv
red
cell
unit
often
leucopen
compar
without
viral
infect
differ
probabl
due
higher
frequenc
haematolog
malign
associ
treatment
modal
miss
data
identifi
confound
per
determin
maximum
crp
valu
measur
patient
risk
period
tabl
si
number
case
control
diagnos
per
type
infect
present
tabl
iii
patient
presenc
absenc
certain
type
infect
could
determin
major
case
due
unestablish
origin
inflammatori
condit
ie
infect
inflammatori
caus
order
avoid
misclassif
omit
patient
correspond
analysi
mild
bacteri
infect
associ
alloimmunis
patient
sever
tissueinvas
bacteri
infect
tend
toward
increas
alloimmunis
risk
adjust
rr
ci
tabl
iii
rel
risk
increas
signific
infect
accompani
longlast
fever
adjust
rr
ci
fever
present
least
day
tabl
iv
time
fever
ie
occur
close
implic
transfus
time
point
risk
period
influenc
rr
tabl
siv
sensit
analysi
patient
origin
omit
analysi
sever
bacteri
infect
n
chang
rr
tabl
sv
given
alloantibodi
e
c
w
le
le
b
lu
also
form
natur
eg
respons
microbi
epitop
exposur
rather
transfusionrel
red
cell
exposur
reid
et
al
evalu
possibl
associ
induct
antibodi
variou
infect
use
pearson
chisquar
test
distribut
alloantibodi
known
also
occur
natur
differ
patient
without
sever
bacteri
infect
tabl
v
interestingli
patient
gramneg
bacteraemia
tend
demonstr
reduc
alloimmunis
rate
adjust
rr
ci
gramposit
bacteraemia
associ
red
cell
alloimmunis
tabl
iii
exclud
potenti
dilut
exist
effect
contamin
blood
cultur
posit
cn
also
evalu
associ
noncn
gramposit
bacteraemia
alloimmunis
rr
analysi
ident
origin
calcul
rr
viral
diseas
tend
associ
increas
red
cell
alloimmunis
incid
adjust
rr
associ
dissemin
viral
infect
ci
presenc
fever
influenc
rr
viral
infect
tabl
iv
adjust
identifi
potenti
confound
detail
see
tabl
siii
number
patient
presenc
absenc
given
infect
could
determin
present
rr
rel
risk
ci
confid
interv
nc
comput
adjust
number
transfus
red
cell
unit
hospit
adjust
identifi
potenti
confound
detail
see
tabl
siii
fungal
infect
well
candidaemia
invas
aspergillu
infect
separ
associ
heterogen
rr
reach
signific
tabl
iii
neither
leucocytosi
crp
level
associ
red
cell
alloimmunis
sensit
analysi
paramet
determin
within
week
follow
implic
transfus
chang
result
tabl
svi
studi
first
kind
transfus
patient
suggest
possibl
associ
infecti
condit
red
cell
alloimmunis
specif
observ
suggest
alloimmunis
influenc
type
intens
patient
inflammatori
respons
infect
summari
sever
tissueinvas
bacteri
viral
infect
associ
increas
incid
alloimmunis
rr
ci
ci
contrast
gramneg
bacteraemia
coincid
twofold
reduct
alloimmunis
risk
rr
ci
find
certainli
requir
addit
confirmatori
research
howev
seem
biolog
plausibl
line
prior
anim
experi
observ
hendrickson
et
al
hendrickson
et
al
hendrickson
et
al
smith
et
al
first
longlast
fever
sever
bacteri
infect
associ
substanti
increas
risk
rr
ci
persist
fever
could
reflect
sever
bacteri
infect
induc
profound
inflammatori
respons
altern
addit
fever
might
due
concomit
inflammatori
condit
yet
explan
consist
danger
model
matzing
postul
immun
respons
facilit
pathogenassoci
molecular
pattern
structur
releas
cell
undergo
stress
matzing
gallucci
matzing
kawai
akira
second
although
ci
encompass
ie
null
effect
warrant
firm
conclus
observ
substanti
increas
alloimmunis
rate
patient
system
viral
infect
murin
experi
show
similar
effect
poli
c
hendrickson
et
al
hendrickson
et
al
hendrickson
et
al
smith
et
al
synthet
viral
rna
analogu
agon
tolllik
receptor
tlr
alexopoul
et
al
poli
c
effect
attribut
increas
dendrit
cell
consumpt
transfus
cell
upregul
costimulatori
molecul
activ
prolifer
naiv
antigenspecif
tcell
hendrickson
et
al
hendrickson
et
al
exist
molecular
mimicri
certain
viral
peptid
tcell
red
cell
antigen
epitop
also
suggest
although
observ
effect
polyomaviru
infect
mice
reach
statist
signific
hudson
et
al
although
analys
associ
latent
viral
infect
red
cell
alloimmunis
might
also
relev
addit
assess
possibl
differ
effect
rna
dna
virus
prevent
low
event
number
third
observ
twofold
alloimmunis
incid
reduct
gramneg
bacteraemia
analog
viral
infect
find
requir
confirmatori
research
yet
corrobor
anim
experi
show
significantli
attenu
alloimmunis
respons
upon
lipopolysaccharid
lp
pretreat
mice
hendrickson
et
al
lp
endotoxin
outer
cell
membran
gramneg
bacteria
strongli
stimul
innat
immun
agon
macrophag
dendrit
cell
convers
lp
also
implic
transient
possibl
selfprotect
immun
paralysi
known
lp
toler
lauw
et
al
weijer
et
al
gould
et
al
restimul
lp
respect
initi
blockag
cell
function
via
impair
releas
tumour
necrosi
factor
interleukin
il
monocyt
dendrit
cell
togeth
diminish
upregul
major
histocompat
complex
classii
costimulatori
molecul
mattern
et
al
gould
et
al
regulatori
cell
select
express
tlr
includ
lpsinduc
prolifer
might
also
contribut
observ
effect
mice
human
caramalho
et
al
final
exclud
indirect
role
gramneg
bacteraemia
red
cell
alloimmunis
due
common
associ
modul
inde
suppress
mitogen
b
lymphocyt
respons
observ
follow
administr
antibiot
includ
cephalosporin
antibiot
class
frequent
use
treatment
gramneg
bacteri
infect
borowski
et
al
pomorskamol
et
al
intrigu
contrast
effect
observ
gramneg
bacteraemia
observ
associ
gramposit
bacteraemia
red
cell
alloimmunis
common
lower
degre
acut
inflamm
evok
gramposit
compar
gramneg
bloodstream
infect
due
differ
virul
mechan
form
one
hypothet
explan
wang
et
al
gould
et
al
abe
et
al
despit
rr
fungal
infect
differ
significantli
gramneg
bacteraemia
heterogen
rr
individu
fungal
microorgan
lack
support
evid
prevent
tent
infer
inde
contrast
estim
rr
one
report
suggest
neonat
alloimmunis
relat
dissemin
histoplasmosi
infect
hata
et
al
ultim
goal
studi
would
establish
accur
alloimmunis
predict
model
serv
practic
tool
riskbas
extend
match
model
would
feasibl
base
routin
measur
patient
paramet
perspect
observ
associ
level
leucocytosi
crp
alloimmunis
possibl
due
multifactori
natur
paramet
biomark
eg
cytokin
level
immun
cell
subset
might
better
discrimin
howev
could
evalu
current
studi
studi
design
result
interpret
requir
addit
remark
first
incidencedens
sampl
strategi
guarante
select
control
similarli
expos
match
case
rothman
herebi
rr
influenc
transfus
burden
main
determin
red
cell
alloimmunis
zalpuri
et
al
ever
et
al
second
identifi
implic
transfus
could
studi
condit
present
given
time
durat
alloimmunis
modul
current
unknown
also
probabl
differ
per
risk
factor
chose
seemingli
larg
risk
period
preced
implic
transfus
although
one
could
argu
strategi
could
possibl
dilut
effect
hand
assur
inclus
factor
influenc
time
exposur
exampl
repeat
lp
exposur
might
induc
state
toler
persist
day
cross
addit
recent
studi
show
poli
c
facilit
red
cell
alloimmunis
least
day
maximum
effect
reach
day
administr
elayeb
et
al
valid
chosen
risk
period
length
sensit
analysi
infect
diagnos
week
preced
follow
implic
transfus
chang
conclus
data
shown
similarli
durat
fever
accompani
sever
bacteri
infect
rather
time
risk
period
affect
alloimmunis
aim
target
like
first
initi
alloimmun
respons
limit
risk
period
first
day
follow
implic
transfus
third
actual
lag
period
per
antigenspecif
antibodi
current
unknown
chosen
lag
period
day
might
complet
prevent
exclus
patient
demonstr
recal
respons
includ
women
immunis
due
prior
pregnanc
direct
antiglobulin
test
perform
routin
basi
shortli
follow
transfus
help
identifi
patient
howev
nonrhd
alloantibodi
form
first
trimest
pregnanc
koelewijn
et
al
believ
substanti
influenc
previou
pregnanc
unlik
moreov
erron
consid
substanti
amount
boost
reaction
primari
alloimmunis
event
would
bias
rr
toward
nulleffect
inde
sensit
analysi
exclud
patient
alloantibodi
discov
second
week
follow
first
antigenincompat
transfus
substanti
chang
rr
data
shown
conclus
believ
eventu
bia
due
choic
lag
period
small
fourth
avoid
invalid
infer
due
misclassif
defin
patient
nonestablish
aetiolog
inflammatori
phenotyp
expos
patient
exampl
vascular
compromis
patient
diagnos
osteomyel
wound
cultur
posit
staphylococcu
aureu
might
repres
normal
skin
flora
colon
primari
ischaem
wound
consequ
analysi
sever
bacteri
infect
includ
patient
sensit
analysi
confirm
result
affect
possibl
misclassif
bia
conclus
data
suggest
potenti
risk
modifi
influenc
infectionassoci
inflamm
red
cell
alloimmunis
transfus
patient
alloimmunis
seem
induc
sever
bacteri
viral
infect
might
skew
toward
protect
presenc
gramneg
bacteraemia
confirmatori
research
need
ultim
identifi
highrisk
patient
consequ
better
target
alloc
extens
match
red
cell
unit
